1 of 1
Story summary
- The U.S. Supreme Court ruled 9-0 that Hikma may sell generic Vascepa without patent liability.
- Justice Ketanji Brown Jackson wrote the opinion, finding Amarin failed to prove active inducement.
- The decision reversed the Federal Circuit, which had previously overturned a Delaware district court dismissal.
- President Donald Trump’s administration backed Hikma, arguing the case could affect drug prices.
- Amarin reported $213.6 million Vascepa revenue for 2025 and expressed disappointment.
